Pale Fire Capital SE Purchases 8,985 Shares of Liquidia Corporation $LQDA

Pale Fire Capital SE increased its position in Liquidia Corporation (NASDAQ:LQDA) by 2.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 388,377 shares of the company’s stock after buying an additional 8,985 shares during the quarter. Liquidia accounts for approximately 1.2% of Pale Fire Capital SE’s holdings, making the stock its 14th biggest holding. Pale Fire Capital SE owned about 0.44% of Liquidia worth $14,657,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Liquidia by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after buying an additional 1,700 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Liquidia by 10.7% during the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Liquidia by 15.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after acquiring an additional 16,022 shares during the last quarter. Creative Planning boosted its holdings in shares of Liquidia by 40.7% during the second quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after purchasing an additional 7,765 shares during the period. Finally, Legal & General Group Plc boosted its holdings in shares of Liquidia by 13.4% during the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after purchasing an additional 11,111 shares during the period. 64.54% of the stock is currently owned by institutional investors.

Liquidia Trading Down 3.2%

NASDAQ:LQDA opened at $86.22 on Friday. The company has a 50-day moving average price of $71.22 and a 200-day moving average price of $50.08. The stock has a market cap of $7.67 billion, a price-to-earnings ratio of 615.90 and a beta of 0.55. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 12 month low of $16.82 and a 12 month high of $91.10.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The company had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. The business’s quarterly revenue was up 4187.1% compared to the same quarter last year. Equities analysts predict that Liquidia Corporation will post 3.02 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on LQDA shares. HC Wainwright set a $36.00 target price on Liquidia in a research note on Friday. Wells Fargo & Company upped their price target on Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Raymond James Financial reiterated a “strong-buy” rating and issued a $68.00 price objective on shares of Liquidia in a report on Thursday, June 4th. Bank of America reiterated a “neutral” rating and issued a $79.00 price objective (up from $64.00) on shares of Liquidia in a research report on Monday, June 29th. Finally, Piper Sandler set a $129.00 target price on Liquidia in a research note on Friday. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $86.18.

Insider Buying and Selling at Liquidia

In other news, insider Sanjeev Khindri sold 1,185 shares of the stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $71.51, for a total value of $84,739.35. Following the completion of the transaction, the insider owned 65,947 shares of the company’s stock, valued at approximately $4,715,869.97. This represents a 1.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Kaseta sold 20,430 shares of the firm’s stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $71.51, for a total value of $1,460,949.30. Following the completion of the transaction, the chief financial officer owned 345,805 shares of the company’s stock, valued at approximately $24,728,515.55. The trade was a 5.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 2,022,134 shares of company stock worth $129,579,224. Insiders own 25.60% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).